These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 19337557

  • 41. Are HIV positive patients resistant to statin therapy?
    Johns KW, Bennett MT, Bondy GP.
    Lipids Health Dis; 2007 Oct 24; 6():27. PubMed ID: 17958912
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
    Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM.
    Circulation; 2010 Mar 09; 121(9):1069-77. PubMed ID: 20176986
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients.
    Semenova AE, Sergienko IV, Masenko VP, Ezhov MV, Gabrusenko SA, Kuharchuk VV, Belenkov YN.
    Acta Cardiol; 2009 Jun 09; 64(3):405-9. PubMed ID: 19593954
    [Abstract] [Full Text] [Related]

  • 48. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group.
    Hongo M, Kumazaki S, Izawa A, Hidaka H, Tomita T, Yazaki Y, Kinoshita O, Ikeda U.
    Circ J; 2011 Jun 09; 75(11):2660-7. PubMed ID: 21857142
    [Abstract] [Full Text] [Related]

  • 49. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial.
    Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, Vriz O, Pasotti M, Gorini M, Marchioli R, Maggioni A, Tavazzi L, GISSI-HF investigators.
    Eur J Heart Fail; 2010 Dec 09; 12(12):1345-53. PubMed ID: 20952767
    [Abstract] [Full Text] [Related]

  • 50. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.
    Rosenson RS, Otvos JD, Hsia J.
    Diabetes Care; 2009 Jun 09; 32(6):1087-91. PubMed ID: 19265025
    [Abstract] [Full Text] [Related]

  • 51. Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease.
    Kurtoglu E, Balta S, Sincer I, Altas Y, Atas H, Yilmaz M, Korkmaz H, Erdem K, Akturk E, Demirkol S, Can C.
    Angiology; 2014 Oct 09; 65(9):788-93. PubMed ID: 24163120
    [Abstract] [Full Text] [Related]

  • 52. The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia.
    Demir V, Doğru MT, Ede H, Yilmaz S, Alp C, Celik Y, Yildirim N.
    Cardiovasc J Afr; 2014 Oct 09; 29(3):162-166. PubMed ID: 29528361
    [Abstract] [Full Text] [Related]

  • 53. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients.
    Egede R, Jensen LO, Hansen HS, Antonsen L, Hansen KN, Junker A, Thayssen P.
    Int J Cardiol; 2012 Jul 26; 158(3):376-9. PubMed ID: 21349594
    [Abstract] [Full Text] [Related]

  • 54. [Influence of perindopril, rosuvastatin, or omega-3 polyunsaturated fatty acids on efficacy of antirecurrence therapy with sotalol in patients with persistent atrial fibrillation].
    Kanorskiĭ SG, Bodrikova VV, Kanorskaia IuS.
    Kardiologiia; 2007 Jul 26; 47(12):39-44. PubMed ID: 18260977
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
    Singh S, Willig JH, Mugavero MJ, Crane PK, Harrington RD, Knopp RH, Kosel BW, Saag MS, Kitahata MM, Crane HM.
    Clin Infect Dis; 2011 Feb 01; 52(3):387-95. PubMed ID: 21189273
    [Abstract] [Full Text] [Related]

  • 58. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.
    Sawara Y, Takei T, Uchida K, Ogawa T, Yoshida T, Tsuchiya K, Nitta K.
    Intern Med; 2008 Feb 01; 47(17):1505-10. PubMed ID: 18758125
    [Abstract] [Full Text] [Related]

  • 59. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 01; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 60. Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1.
    Colucci R, Fornai M, Duranti E, Antonioli L, Rugani I, Aydinoglu F, Ippolito C, Segnani C, Bernardini N, Taddei S, Blandizzi C, Virdis A.
    Br J Pharmacol; 2013 Jun 01; 169(3):554-66. PubMed ID: 22817606
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.